Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation

被引：0
作者：
Alexandros Briasoulis
Anupama Kottam
Mazhar Khan
Luis Afonso
机构：
[1] Wayne State University/Detroit Medical Center,Division of Cardiology
来源：
Journal of Thrombosis and Thrombolysis | 2015年 / 40卷
关键词：
Novel oral anticoagulants; Warfarin; Cardioversion; Atrial fibrillation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent trials on novel oral anticoagulants (NOAC) in patients undergoing cardioversion showed that NOACs are as safe and effective as treatment with vitamin K antagonists in patients with atrial fibrillation undergoing electric or pharmacological cardioversion. We conducted an EMBASE and MEDLINE search for studies in which patients undergoing cardioversion were assigned to treatment with NOACs versus VKAs. We identified one prospective randomized study and three post hoc analysis of randomized trials which enrolled 2,788 controls that received NOACs and 1,729 patients that received VKAs. NOACs and VKAs had comparable effects on the rates of stroke/thromboembolism, major bleeding events and all-cause mortality. NOACs are safe and effective alternatives to VKA in patients with AF undergoing cardioversion.
引用
收藏
页码：139 / 143
页数：4
相关论文
共 50 条
  • [1] Klein AL(2001)Assessment of cardioversion using transesophageal echocardiography investigators. use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 1411-1420
  • [2] Grimm RA(2014)AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society J Am Coll Cardiol 123 131-136
  • [3] Murray RD(2011)Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 61 1998-2006
  • [4] Apperson-Hansen C(2013)Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 63 1082-1087
  • [5] Asinger RW(2014)Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) J Am Coll Cardiol 343 d5928-855
  • [6] Black IW(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 19 851-1366
  • [7] Davidoff R(1992)Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 22 1359-undefined
  • [8] January CT(1993)Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography J Am Coll Cardiol undefined undefined-undefined
  • [9] Wann LS(undefined)undefined undefined undefined undefined-undefined
  • [10] Alpert JS(undefined)undefined undefined undefined undefined-undefined
12345